Showing results for:

Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

– First Clinical Study of a Central Nervous System-Administered RNAi Therapeutic Showed Rapid and Robust Target Engagement with Sustained Effect Over 6 Months with a Single Dose – – ALN-APP Continues to Demonstrate an Encouraging Clinical Safety and Tolerability Profile...

Exxon forging ahead with pipeline projects in South America, emphasizing gas development agenda

Gas remains key to ExxonMobil’s development agenda as seen by the company’s acceleration of two major pipeline projects in the South American region.  Over in Argentina, Exxon recently commenced the engineering study phase for the development of a new pipeline...

First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer

Phase 2 MATISSE trial is evaluating IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with Imfinzi (durvalumab) and chemotherapy in early stage lung cancer IPH5201 is developed in collaboration with AstraZeneca MARSEILLE, France--(BUSINESS WIRE)--#immunotherapy--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)...

CANbridge Reports Positive Preliminary Data in the Omoprubart (CAN106) Phase 1b Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH) in China

Promising Efficacy and Safety With Four-Week Extended Dosing Data Shows Dose-Dependent Reduction of LDH and Increased Hemoglobin Levels That Demonstrate Clinically Meaningful Hemolysis Inhibition CANbridge Plans to Advance to Pivotal Trial CANbridge to Hold Investor CallBEIJING & BURLINGTON, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc....

Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease

- Data Presented During Oral Session at EASL 2023 Demonstrate Fazirsiran’s Promising Impact on Key Markers of Liver Disease - AATD-LD is a Rare Genetic Disease Affecting Children and Adults with no Approved Treatments - Takeda and Arrowhead are Advancing Fazirsiran...

Highest to date: Liza field output was 11.6 million barrels in May 2023

ExxonMobil’s Liza projects produced 11.6 million barrels of crude in May, at 374,450 barrels per day (bpd). This was constituted by production of 4.8 million barrels at Liza Phase 1, and 4.8 million barrels at Phase 2.  May output also...

Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions

– All six patients treated with VX-880 engrafted islet cells, produced endogenous insulin (C-peptide) and had improved glycemic control while reducing or eliminating insulin use – – The two patients with at least one year of follow-up met the criteria...

Stellantis, Archer Move Partnership from ‘Concept Phase’ to ‘Execution Phase’

Construction is well underway on the world’s first high-volume eVTOL aircraft manufacturing facility in Covington, Georgia, USA Experienced Stellantis personnel are providing expertise alongside Archer teams to prepare efficient, innovative manufacturing operations Stellantis recently increased its strategic shareholding in Archer through...

BeiGene Highlights Significant BRUKINSA® (zanubrutinib) Data at the 17th International Conference on Malignant Lymphoma

Oral presentation for the ROSEWOOD trial of BRUKINSA in relapsed or refractory follicular lymphoma Additional presentations expand existing evidence base for BRUKINSA across B-cell malignancies BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global...

Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma

Efficacy results of lacutamab in Mycosis Fungoides according to updated lymph node classification in the TELLOMAK Phase 2 study in advanced cutaneous T cell lymphomas MARSEILLE, France--(BUSINESS WIRE)--#ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today...

Latest News

IEA warns of major drop in oil investment as clean energy gains momentum

Upstream oil investment is expected to decline by 6% in 2025, marking the first drop since 2020 and the...